CN114206944A - 用于治疗cmv感染相关疾病的融合毒素蛋白 - Google Patents

用于治疗cmv感染相关疾病的融合毒素蛋白 Download PDF

Info

Publication number
CN114206944A
CN114206944A CN202080050524.5A CN202080050524A CN114206944A CN 114206944 A CN114206944 A CN 114206944A CN 202080050524 A CN202080050524 A CN 202080050524A CN 114206944 A CN114206944 A CN 114206944A
Authority
CN
China
Prior art keywords
leu
ala
immunotoxin
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080050524.5A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·尼奇克·克莱达尔
梅特·玛丽·罗斯基尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Danmarks Tekniske Universitet
Original Assignee
Københavns Universitet
Danmarks Tekniske Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet, Danmarks Tekniske Universitet filed Critical Københavns Universitet
Publication of CN114206944A publication Critical patent/CN114206944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080050524.5A 2019-07-12 2020-06-25 用于治疗cmv感染相关疾病的融合毒素蛋白 Pending CN114206944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186000 2019-07-12
EP19186000.6 2019-07-12
PCT/EP2020/067785 WO2021008840A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to cmv infections

Publications (1)

Publication Number Publication Date
CN114206944A true CN114206944A (zh) 2022-03-18

Family

ID=67437717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080050524.5A Pending CN114206944A (zh) 2019-07-12 2020-06-25 用于治疗cmv感染相关疾病的融合毒素蛋白

Country Status (10)

Country Link
US (1) US20220281933A1 (https=)
EP (1) EP3997107A1 (https=)
JP (1) JP2022540877A (https=)
KR (1) KR20220032610A (https=)
CN (1) CN114206944A (https=)
AU (1) AU2020312560A1 (https=)
BR (1) BR112022000417A2 (https=)
CA (1) CA3146798A1 (https=)
MX (1) MX2022000433A (https=)
WO (1) WO2021008840A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4301394A1 (en) * 2021-03-03 2024-01-10 Synklino ApS Compositions for ex vivo organ care

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020176870A1 (en) * 2001-02-02 2002-11-28 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20030175681A1 (en) * 2000-08-30 2003-09-18 Schall Thomas J. Inhibition of CMV infection and dissemination
EP2038302A2 (en) * 2006-07-03 2009-03-25 INAGEN ApS Immunotoxins for the treatment of diseases related to cmv infection
US20120141538A1 (en) * 2008-12-17 2012-06-07 Universite Pierre Et Marie Curie -Paris Vi Modulators of the cx3cri receptor and therapeutic uses thereof
US20140220062A1 (en) * 2011-09-09 2014-08-07 Merck Sharp & Dohme Corp. Conditional replicating cytomegalovirus as a vaccine for cmv
CN107438625A (zh) * 2015-02-26 2017-12-05 Var2制药有限公司 使用嵌合抗原受体（cars）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的cars的癌症的免疫治疗靶向

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849960B2 (en) * 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175681A1 (en) * 2000-08-30 2003-09-18 Schall Thomas J. Inhibition of CMV infection and dissemination
US20020176870A1 (en) * 2001-02-02 2002-11-28 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2038302A2 (en) * 2006-07-03 2009-03-25 INAGEN ApS Immunotoxins for the treatment of diseases related to cmv infection
US20100048470A1 (en) * 2006-07-03 2010-02-25 Thomas Nitschke Kledal Immunotoxins for the treatment of diseases related to cmv infection
US20120141538A1 (en) * 2008-12-17 2012-06-07 Universite Pierre Et Marie Curie -Paris Vi Modulators of the cx3cri receptor and therapeutic uses thereof
US20140220062A1 (en) * 2011-09-09 2014-08-07 Merck Sharp & Dohme Corp. Conditional replicating cytomegalovirus as a vaccine for cmv
CN107438625A (zh) * 2015-02-26 2017-12-05 Var2制药有限公司 使用嵌合抗原受体（cars）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的cars的癌症的免疫治疗靶向

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NCBI: "Exotoxin A [Pseudomonas aeruginosa]", WP_003112478.1 *
SPIESS等: "Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2017, no. 01, pages 1 - 2, XP055655094, DOI: 10.1155/2017/4069260 *
SPIESS等: "Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 27, pages 5 *
陈贵海, 周江宁, 王明丽: "人巨细胞病毒潜伏感染机制研究新进展", 病毒学报, no. 04, pages 382 - 384 *

Also Published As

Publication number Publication date
MX2022000433A (es) 2022-04-25
US20220281933A1 (en) 2022-09-08
BR112022000417A2 (pt) 2022-03-03
EP3997107A1 (en) 2022-05-18
CA3146798A1 (en) 2021-01-21
WO2021008840A1 (en) 2021-01-21
AU2020312560A1 (en) 2022-03-03
JP2022540877A (ja) 2022-09-20
KR20220032610A (ko) 2022-03-15

Similar Documents

Publication Publication Date Title
CN102281890B (zh) Sparc结合肽及其应用
CN108137671B (zh) 可溶性pdl-1分子
US12377294B2 (en) Anti-CD3 antibody folate bioconjugates and their uses
ES2327986T3 (es) Liberacion intranuclear de compuestos dirigida por la proteina de choque termico de 70 kd.
CA2295189C (en) Type-1 ribosome-inactivating protein
JPH11505805A (ja) 治療的処置のための核酸およびリガンドを含有する組成物
CN114206944A (zh) 用于治疗cmv感染相关疾病的融合毒素蛋白
EP1636263B1 (en) Pegylated soluble gp130-dimers useful as a medicament
US6395875B1 (en) Recombinant soluble adenovirus receptor
US20110015368A1 (en) Cd4-receptor-derived peptides and method for the preparation thereof
JP2001521733A (ja) ヒト上皮増殖因子とヒトアンギオゲニンの融合タンパク質およびその製造方法
WO2014044793A2 (en) Cd22-binding peptides
CN101070350A (zh) 针对cd13的靶向肽与力达霉素构成的强化融合蛋白ngr－ldp－ae
CN101914161A (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
WO2015055148A1 (zh) Yap蛋白抑制多肽及其应用
CN114341196B (zh) 融合蛋白及其用途
JP2006527192A (ja) 血管内皮増殖因子融合構築物およびその使用方法
CN108295242B (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
Roudkenar et al. Selective cytotoxicity of recombinant STXA1-GM-CSF protein in hematopoetic cancer cells
WO2018219301A1 (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US10010625B2 (en) Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin
CN113121668B (zh) PEG修饰的可抑制gp96的多肽、其制备方法及用途
JP7303189B2 (ja) 網膜色素変性症治療用ペプチド
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
KR20130033273A (ko) 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20250822

AD01 Patent right deemed abandoned